Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4088 | Treatment as usual vitamin D Wiki | 1.00 |
| drug1775 | Hydroxychloroquine Wiki | 0.10 |
| drug2916 | Placebo Wiki | 0.04 |
Navigate: Correlations HPO
There is one clinical trial.
The world is currently facing a pandemic with the coronavirus (SARS-CoV-2) which leads to the disease of COVID-19. Risk factors for a poor outcome of COVID-19 have so far been identified as older age and co-morbidity including chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD) and current smoking status. Previous studies found, that vitamin D deficiency is more prevalent among patients with these risk factors. There are observational studies reporting independent associations between low serum concentrations of 25-hydroxyvitamin D (the major circulating vitamin D metabolite) and susceptibility to acute respiratory tract infection. Vitamin D substitution in patients with COVID-19 who show a vitamin D deficiency should therefore be investigated for efficacy and safety. The study is designed as a randomized, placebo-controlled, double blind study. The objective of the study is to test the hypothesis that patients with vitamin D deficiency suffering from COVID-19 treated under standardized conditions in hospital will recover faster when additionally treated with a single high dose of vitamin D compared to standard treatment only.
Description: Overall duration of the hospitalization from day of admission until the day of discharge or fatality
Measure: Length of hospitalization Time: Administration to Discharge from hospital care (mean duration is between 14 and 22 days for Patients with COVID 19)Description: Did the patient need a intensive care treatment during the hospitalization (yes/no)
Measure: Need of intensive care Time: Until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)Description: Day of admission to ICU until discharge or fatality
Measure: Lenght of the Intensive Care Treatment Time: Until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)Description: Percentage of patient died during hospitalization
Measure: Overall mortality Time: During the length of hospitalisation (mean duration is between 14 and 22 days for Patients with COVID-19)Description: percentage of patients with 25-hydroxyvitamin D > 50nmol/L (>20ng/mL) at day 7 - The values of calcium, phosphorus, 24-hydroxyvitamin D, 1.25-dihydroxyvitamin D, parathyroid hormone.
Measure: Development of vitamin D levels Time: Day 1 (Baseline) and Day 7 after the first administration of the high dose vitamin D or the placebo and at discharge (mean hospital stay is between 14 and 22 days for Patients with COVID-19)Description: percentage of patients developing a sepsis
Measure: Development of sepsis Time: During the length of hospitalization (mean duration is between 14 and 22 days for Patients with COVID-19)Description: We assess every other complications which occurs due to COVID-19
Measure: Complications due to COVID-19 Time: During the length of hospitalization (mean duration is between 14 and 22 days for Patients with COVID-19)Description: The BP will be assessed daily in mmHg
Measure: Blood pressure (BP) Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)Description: The heart rate will be assessed daily in bpm
Measure: Heart rate Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID-19)Description: The SpO2 will be assessed daily in %
Measure: Peripheral oxygen saturation (SpO2) Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)Description: Requirement for oxygen will be assessed daily (yes/no) if yes how many liters per minute
Measure: Percentage of patients who require oxygen Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)Description: Breathing frequence will be assessed daily in breaths per minute
Measure: Breathing frequency Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)Description: GCS will be assessed daily 3 to 15 points. It describes the extent of impaired consciousness. 15 points means no impairment, 3 points means severe impairment of consciousness.
Measure: Glasgow Coma Scale (GCS) Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)Description: Assessing the history of smoking in pack years (PY). the assessment will be made with the following options for answering Current smoker: Smoking for how many years? Cigarettes per day? Former smoker, how many years smoked? How many cigarettes per day Life-long non-smoker
Measure: Percentage of patients are smokers, former smokers or lifelong non-smokers Time: Assessing of the smoking Status at BasleineDescription: Assessed in No/ Mild/ Moderate /Severe
Measure: Current Symptoms Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)Description: Temperature will be assessed daily in degrees celsius
Measure: Temperature Time: Daily until discharge or fatality (mean duration is between 14 and 22 days for Patients with COVID 19)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports